Company intelligence
Huntsman Cancer Institute
Cancer research, care, and education at the University of Utah. NCI-Designated Comprehensive Cancer Center.
About Huntsman Cancer Institute
Huntsman Cancer Institute at the University of Utah is the National Cancer Institute-designated Comprehensive Cancer Center for Utah, Idaho, Montana, Nevada, and Wyoming. With a legacy of innovative cancer research, groundbreaking discoveries, and world-class patient care, we are transforming the way cancer is understood, prevented, diagnosed, treated, and survived. Huntsman Cancer Institute focuses on delivering the most advanced cancer healing and prevention through scientific breakthroughs and cutting-edge technology to advance cancer treatments beyond the standard of care today. We have more than 300 open clinical trials and 250 research teams studying cancer. More genes for inherited cancers have been discovered at Huntsman Cancer Institute than at any other cancer center. Our scientists are world-renowned for understanding how cancer begins and using that knowledge to develop innovative approaches to treat each patient’s unique disease. Huntsman Cancer Institute was founded by Jon M. and Karen Huntsman.
Verified activity
Signals from Huntsman Cancer Institute
7 published signals
People
Huntsman Cancer Institute employee Paige Sinicki completed radiation in June 2026 and was cleared to play and made her professional debut one month later.
Reported by Huntsman Cancer Institute
Presence & Recognition
Huntsman Cancer Institute was recognized at a cornerstone celebration at the Vineyard location to honor patients, staff, emerging researchers, and donors.
Reported by Huntsman Cancer Institute
Operations & Supply
Huntsman Cancer Institute broke ground on the future campus in Vineyard in Utah County, with 830 foundation supports installed.
Reported by Huntsman Cancer Institute
Presence & Recognition
Huntsman Cancer Institute published Ece Uzun, PhD, MS, FAMIA for the upcoming webinar on Clinical Bioinformatics and Multimodal AI: Advancing Molecular Diagnostics and Cancer Recurrence Prediction on September 18, 2026.
Reported by Aik Choon Tan
Research & Knowledge
Huntsman Cancer Institute enrolled Gary in a clinical trial studying daraxonrasib, a new oral treatment approved by the FDA.
Reported by Huntsman Cancer Institute
People
Huntsman Cancer Institute appointed Kelli Thorne, MPH, CCRP, director of the Research Compliance Office to the AACI Clinical Research Innovation Steering Committee.
Reported by Huntsman Cancer Institute
Research & Knowledge
Huntsman Cancer Institute published a new publication with Manish Kohli, MD, Zaki Fadlullah Wilmot, Benjamin Haaland, and Liang Wang on the clinico-genomic prognostic nomogram (CGPS) of metastatic castration-resistant prostate cancer.
Reported by Aik Choon Tan